Integrated drug discovery panel – your questions answered!
ON-DEMAND By Charles River
During this peer panel discussion, team members from Charles River discussed their views and strategies on Drug Discovery...
List view / Grid view
Webinars
Webinar: Phenotypic assays for CNS disease drug discovery
ON-DEMAND By Charles River Laboratories
In this webinar, we highlight in vitro models and phenotypic assays to discover and validate novel targets and promising lead molecules...
Using open science to develop Pediatric Cancer Drugs
ON-DEMAND By Charles River Laboratories
The webinar speakers highlight the collaboration between patient groups, charities, and academia led to the development of inhibitors targeting gliomas.
Skin toxicity mechanisms associated with mGluR5 negative allosteric modulators
ON-DEMAND By DiscoverX
In this webinar, DiscoverX Corporation discuss three negative allosteric modulators of metabotropic glutamate receptors, developed by Pfizer, which recently failed in preclinical development due to delayed type IV skin hypersensitivity observed in non-human primates...
The mast cell receptor MrgX2 and drug-induced anaphylaxis
ON-DEMAND By DiscoverX
The goal of this webinar is to illustrate how knowledge of MrgX2 activity across a panel of mammalian species can be integrated into drug development to influence choice of compound, species model and dosing regimen...
Cognitive Phenotypes in MS Mouse Models
ON-DEMAND By Charles River Laboratories
40-65% of MS patients have cognitive impairment and touchscreen testing in animal models is a new method to test cognitive issues in MS animal models...
High performance computing for high content screening – A case study
ON-DEMAND By PerkinElmer
In this webinar, PerkinElmer and AMRI will present a case study wherein high-performance computing (HPC) was leveraged for enhanced performance in image and data analysis of High Content Screening experiments...
Novel readouts for neuropathic pain models
ON-DEMAND By Charles River
This webinar reviews standard neuropathic pain models and readouts and will include fine motor kinematic analysis to highlight gait changes...
Designing a Novel Cancer Drug: From Hit ID to Candidate
ON-DEMAND By Charles River
Discover how their multidisciplinary approach to hit ID, design and synthesis of novel chemical templates and development of targeted in vitro and in vivo assays resulted in the nomination of the first development candidate in just over two years...
Acute and inflammatory in vivo pain models
ON-DEMAND By Charles River
This webinar discusses our newly validated acute and inflammatory in vivo pain models, including information on how they were validated and how they can be used to test new pain treatment compounds, eventually leading to clinical translation...
Assessing neurological ion channel therapeutic and liability targets
ON-DEMAND By Charles River
This webinar explores neurological ion channel therapeutic and liability targets, featuring four subtypes of NMDA receptors. We also discuss the rationale and options for assessment of therapeutic compounds on panels of CNS ion channels for evaluating their risk for CNS liabilities...
Vertical integration of CRISPR/Cas9 in drug discovery
ON-DEMAND By Charles River
In this webinar, Charles River discuss the utilisation of CRISPR/Cas9 technology in drug discovery, with an emphasis on generation of in vitro models for high-throughput screening, and creating new mouse models...
Label-free ultra-high-throughput screening by MALDI Mass Spectrometry
ON-DEMAND By Bruker
This webinar discusses a new MALDI Time-of-flight (TOF) Mass Spectrometer, designed for ultra-fast label-free screening of biochemical assays...
New strategy to identify small molecule therapies
ON-DEMAND By Charles River
This webinar details a successful new strategy to identify small molecule therapies to treat protein-destabilizing monogenic disorders...
Fine Motor Kinematics in In Vivo Pharmacology
ON-DEMAND By Charles River
This webinar details a novel automated and high-precision system to successfully analyze early changes in muscular or neuronal function in disease models...
